

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 55384

**Title:** Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update

**Reviewer's code:** 02904354

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Chief Physician, Associate Professor, Doctor, Postdoc

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2020-03-16

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-03-24 03:16

**Reviewer performed review:** 2020-03-25 09:21

**Review time:** 1 Day and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This paper deserves the publication in this journal, but some comments should be addressed. Recently, there are several review papers focusing on the role of glucagon-like peptide-1 receptor agonists in NAFLD and NASH. Please acknowledge their contributions and your novelty. Various metabolism disorders, including thyroid function (PMID: 30224316), are associated with the occurrence of NAFLD. In the Introduction section, please do not forget their role. Various types of glucagon-like peptide-1 receptor agonists have their own mechanisms. So it is important to briefly and clearly outline their own advantages and disadvantages for NAFLD in conclusion section. Lixisenatide and Dulaglutide paragraphs are too short compared to the Exenatide paragraph. I suggest to expand their animal studies. Grammar and spelling errors should be carefully revised, such as "... showed a improvement in ...".

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 55384

**Title:** Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update

**Reviewer's code:** 00030389

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Greece

**Manuscript submission date:** 2020-03-16

**Reviewer chosen by:** Jie Wang

**Reviewer accepted review:** 2020-03-24 04:56

**Reviewer performed review:** 2020-03-26 02:20

**Review time:** 1 Day and 21 Hours

<b>Scientific quality</b>	[ <input checked="" type="radio"/> ] Grade A: Excellent [ <input type="radio"/> ] Grade B: Very good [ <input type="radio"/> ] Grade C: Good [ <input type="radio"/> ] Grade D: Fair [ <input type="radio"/> ] Grade E: Do not publish
<b>Language quality</b>	[ <input checked="" type="radio"/> ] Grade A: Priority publishing [ <input type="radio"/> ] Grade B: Minor language polishing [ <input type="radio"/> ] Grade C: A great deal of language polishing [ <input type="radio"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input type="radio"/> ] Accept (High priority) [ <input checked="" type="radio"/> ] Accept (General priority) [ <input type="radio"/> ] Minor revision [ <input type="radio"/> ] Major revision [ <input type="radio"/> ] Rejection
<b>Re-review</b>	[ <input type="radio"/> ] Yes [ <input type="radio"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors summarized the updated literature data on the beneficial effects of GLP-1RAs in NAFLD/NASH. They showed that both animal and clinical studies are highly promising for the beneficial effect of GLP-1RAs in the treatment of NAFLD. The review is well written. I have no concerns.